BRCA2 and breast carcinoma: For example, advanced breast cancer patients with a germline BRCA1 or BRCA2 PV have a greater benefit to PARP inhibition than individuals with a somatic BRCA1 or BRCA2 PV, and the FDA-approval for PARP inhibition is currently confined to those with a germline PV4.